Published

Emerging from the dark side: new therapeutic applications of scheduled psychoactive substances.

No abstract is available for this record.

Open source BibTeX RIS

Bibliographic context

Journal: Future medicinal chemistry
Date: 2019-01-31
Source: PubMed
DOI: 10.4155/fmc-2018-0447
PubMed: 30763121

Authors

James E Robertshaw TL Westwell AD

Watch author

Topics and keywords

psilocybin General Other MDMA harm reduction healthcare positive psychology psilocybin psychoactive psychotherapy

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New MexicoFrontiers in Public Health · 2026-06-16 EE127 A REVIEW OF HEALTH ECONOMIC ANALYSES OF PSILOCYBIN, MIDOMAFETAMINE(MDMA), AND KETAMINE-BASED TREATMENTS FOR MENTAL HEALTH CAREValue in Health · 2026-05-31 Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b TrialPsychotherapy and Psychosomatics · 2026-05-26 The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising ApproachDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21 Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybinJournal of Pre-Clinical and Clinical Research · 2026-05-11 C29-12 Psilocybin Treatment Could Improve Outcomes for Age-associated Lung DiseasesAmerican Journal of Respiratory and Critical Care Medicine · 2026-04-30 Phase 1 trial suggests benefit of psilocybin in OCD treatmentThe Brown University Psychopharmacology Update · 2026-07-31 Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventionsJournal of Psychedelic Studies · 2026-07-02